Emerging Options for the Prevention and Management of Clostridioides difficile Infection

被引：18
|
作者：
Gonzales-Luna, Anne J. J. [1 ]
Carlson, Travis J. J. [2 ]
Garey, Kevin W. W. [1 ]
机构：
[1] Univ Houston, Coll Pharm, Dept Pharm Practice & Translat Res, 4849 Calhoun Rd, Houston, TX 77204 USA
[2] High Point Univ, Dept Clin Sci, Fred Wilson Sch Pharm, High Point, NC USA
来源：
DRUGS | 2023年 / 83卷 / 02期
关键词：
HEALTH-CARE EPIDEMIOLOGY; FECAL MICROBIOTA TRANSPLANTATION; CLINICAL-PRACTICE GUIDELINES; DISEASES SOCIETY; INTESTINAL MICROBIOTA; TOXOID VACCINE; AMERICA IDSA; DOUBLE-BLIND; VANCOMYCIN; FIDAXOMICIN;
D O I：
10.1007/s40265-022-01832-x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Agents in development for the prevention or treatment of Clostridioides difficile infection can be split into three broad categories: antibiotics, microbiome restoration, and vaccines. Given the extensive list of agents currently in development, this narrative review will focus on agents that have progressed into late-stage clinical trials, defined as having a Phase III clinical trial registered on ClinicalTrials.gov. These agents include one antibiotic (ridinilazole), three live biotherapeutic products (LBPs) (CP101, RBX2660, and SER109), and two toxoid vaccines (PF06425090 and a second toxoid vaccine). As new prevention and treatment strategies enter the market, clinicians and administrators will need knowledge of these products to make rational decisions on how best to adopt them into clinical practice.
引用
收藏
页码：105 / 116
页数：12
相关论文
共 50 条
  • [1] Emerging Options for the Prevention and Management of Clostridioides difficile Infection
    Anne J. Gonzales-Luna
    Travis J. Carlson
    Kevin W. Garey
    [J]. Drugs, 2023, 83 : 105 - 116
  • [2] Recurrent Clostridioides difficile infection: Recognition, management, prevention
    Tsigrelis, Constantine
    [J]. CLEVELAND CLINIC JOURNAL OF MEDICINE, 2020, 87 (06) : 347 - 359
  • [3] Clostridioides difficile infection: an emerging zoonosis?
    Tsai, Chin-Shiang
    Hung, Yuan-Pin
    Lee, Jen-Chieh
    Syue, Ling-Shan
    Hsueh, Po-Ren
    Ko, Wen-Chien
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2021, 19 (12) : 1543 - 1552
  • [4] Emerging Diagnostics in Clostridioides difficile Infection
    Hulme, John P.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (16)
  • [5] Management of Clostridioides difficile Infection
    Clarkin, Christina
    Quist, Stephanie
    Shamis, Renata
    King, Amber E.
    Shah, Bhavik M.
    [J]. CRITICAL CARE NURSE, 2019, 39 (05) : E1 - E12
  • [6] Emerging alternatives against Clostridioides difficile infection
    Romero-Rodriguez, A.
    Martinez de la Pena, C.
    Troncoso-Cotal, S.
    Guzman, C.
    Sanchez, S.
    [J]. ANAEROBE, 2022, 78
  • [7] Novel and emerging sources of Clostridioides difficile infection
    Turner, Nicholas A.
    Smith, Becky A.
    Lewis, Sarah S.
    [J]. PLOS PATHOGENS, 2019, 15 (12)
  • [8] Clostridioides difficile Infection: Update on Management
    Mounsey, Anne
    Smith, Kelly Lacy
    Reddy, Vinay C.
    Nickolich, Sarah
    [J]. AMERICAN FAMILY PHYSICIAN, 2020, 101 (03) : 168 - 175
  • [9] Prevention of Infection due to Clostridium (Clostridioides) difficile
    Krishna, Amar
    Chopra, Teena
    [J]. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2021, 35 (04) : 995 - 1011
  • [10] Prevention and treatment of recurrent Clostridioides difficile infection
    Shin, Jae Hyun
    Warren, Cirle A.
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2019, 32 (05) : 482 - 489
12345